Yearly Archives: 2017


Amorsa Therapeutics Featured in the June Issue of Life Science Leader Magazine

Southborough, MA, June 28, 2017 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders today announced that the company was featured in the June issue of Life Science Leader magazine. Please click here to view the article. About Amorsa Therapeutics Amorsa is an early-stage, neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders including moderate-to-severe pain and treatment-resistant depression. Founded in 2013, Amorsa has assembled a leadership team with experience in building several successful life science companies and has a strong track record in developing novel therapeutic treatments.  More


Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-­‐Resistant Depression

Southborough, MA, January 5, 2017 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has announced a research, option and license agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a novel small molecule drug candidate for treatment-resistant depression based on Amorsa’s proprietary ketamine analog technology. Amorsa’s product candidates are designed to show efficacy as rapidly acting antidepressants with an extended duration of action, possess an attractive side-effect profile, and enable oral dose administration. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, Amorsa will receive an upfront payment, More